Skip to main content
. 2020 Jun 1;9(12):e015513. doi: 10.1161/JAHA.119.015513

Figure 5. Tranilast (TR) suppresses the progression of atherosclerosis in low‐density lipoprotein receptor–deficient (Ldlr−/−) mice (group 2).

Figure 5

A, Diagramed is the regimen for treatment of Ldlr−/− mice (6 to 8 weeks old) with TR (n=8) or vehicle (n=8). The atherosclerotic lesions (B through D), the collagen content in the plaque (E), the fibrous caps and the necrotic core (F), the expression of the indicated proteins (G through I), and the profile of the plasma lipids and lipoproteins (J) in mice were analyzed and quantified as described in Figure 3.